Skip to main content

Table 1 Derivation, p53 and other genomic mutations of breast cancer cell lines used in this study

From: Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1

          

p53 mutation

 

Cell lines

Growth properties

Gene cluster

ER

PR

HER2

Tumor type

Age(years)

Ethnicity

P53 status

Nature

Site

cDNA discription

Protein

Functional impact

Other genomic alterations

MCF-7

Adherent

Luminal

 + 

 + 

–

Adenocarcinoma

69

white

WT

     

CDKN2A; PIK3CA

ZR-75–1

Adherent

Luminal

 + 

–

–

IDC

63

white

WT

     

–

SK-BR-3

Adherent

HER2 + 

–

–

 + 

Adenocarcinoma

43

white

MUT

Missense mutations

5-exon

c.524G > A

p.R175H

Chemoresistance; Angiogenesis; Inflammatory response; Metabolic reprogramming; Genetic Instability; Tumor Cell proliferation; Migration, Invasion and Metastasis

–

DU4475

Suspension

TNBC

–

–

–

Carcinoma

70

white

WT

     

APC; BRAF; RB1

MB-231

Adherent

TNBC

–

–

–

Adenocarcinoma

51

white

MUT

Missense mutations

8-exon

c.839G > A

p.R280K

Chemoresistance; Angiogenesis; Inflammatory response

BRAF; CDKN2A; RAS

HS578T

Adherent

TNBC

–

–

–

Carcinoma

74

white

MUT

Missense mutations

5-exon

c.469G > T

p.V157F

A novel transcriptome regulation

–

HCC1937

Adherent

TNBC

–

–

–

IDC

23

white

MUT

Nonsense mutations

8-exon

c.916C > T

p.R306*

 

BRCA1

  1. ER Estrogen receptor, IDC Invasive ductal carcinoma, PR Progestogen receptor, TNBC Triple-negative breast cancer, WT Wild type, MUT Mutant type